| 1 |
2023 |
Ritwik Maiti, Bhumika Patel, Nrupesh Patel, Mehul Patel, Alkesh Patel, Nirav Dhanesha. Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities, Archives of Pharmacal Research. 2023; 46: 361.
https://doi.org/10.1007/s12272-023-01447-0 |
| 2 |
2023 |
Rafael F. A. Gomes, Bruno M. F. Gonçalves, Késsia H. S. Andrade, Bárbara B. Sousa, Nuno Maulide, Gonçalo J. L. Bernardes, Carlos A. M. Afonso. Unlocking the Potential of Bio‐Based Nitrogen‐Rich Furanic Platforms as Biomass Synthons, Angewandte Chemie International Edition. 2023; 62: e202304449.
https://doi.org/10.1002/anie.202304449 |
| 3 |
2024 |
Feng Wen, Tianhai Lin, Peng Zhang, Yali Shen. RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03), Frontiers in Oncology. 2024; 13: 1233196.
https://doi.org/10.3389/fonc.2023.1233196 |
| 4 |
2023 |
Feng Wen, Tianhai Lin, Peng Zhang, Yali Shen. 2023;
https://doi.org/10.21203/rs.3.rs-2424409/v1 |
| 5 |
2024 |
Fatima Akram, Amna Murrawat Ali, Muhammad Tayyab Akhtar, Taseer Fatima, Ifrah Shabbir, Ikram ul Haq. The journey of antibody-drug conjugates for revolutionizing cancer therapy: A review, Bioorganic & Medicinal Chemistry. 2024; 118010118010.
https://doi.org/10.1016/j.bmc.2024.118010 |
| 6 |
2022 |
Erin F. Cobain, Daniel F. Hayes. Expanding the reach of HER2-targeted therapies: transformation of an historical paradigm, Journal of Clinical Investigation. 2022; 132: e166384.
https://doi.org/10.1172/JCI166384 |
| 7 |
2023 |
Ivana Jarak, Ana Isabel Santos, Ana Helena Pinto, Cátia Domingues, Inês Silva, Raquel Melo, Francisco Veiga, Ana Figueiras. Colorectal cancer cell exosome and cytoplasmic membrane for homotypic delivery of therapeutic molecules, International Journal of Pharmaceutics. 2023; 646: 123456123456.
https://doi.org/10.1016/j.ijpharm.2023.123456 |
| 8 |
2024 |
Xiehui Chen, Changchun Zeng. Pioneering the Way: The Revolutionary Potential of Antibody–Drug Conjugates in NSCLC, Current Treatment Options in Oncology. 2024; 25: 556.
https://doi.org/10.1007/s11864-024-01196-2 |
| 9 |
2024 |
Elisabete Cruz Da Silva, Charlène D’Ancona, Hélène Justiniano, Valérie Calco, Dilara Sensoy, Pascal Villa, Romain Vauchelles, Maxime Lehmann, Laurence Choulier. 2024;
https://doi.org/10.1101/2024.10.22.617611 |
| 10 |
2023 |
Christian Werner Wichmann, Ingrid Julienne Georgette Burvenich, Nancy Guo, Angela Rigopoulos, Alexander McDonald, Diana Cao, Graeme Joseph O'Keefe, Sylvia Jie Gong, Hui Kong Gan, Fiona Elizabeth Scott, Nabendu Pore, Steven Coats, Andrew Mark Scott. Preclinical radiolabeling, in vivo biodistribution and positron emission tomography of a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2, Nuclear Medicine and Biology. 2023; 122-123: 108366108366.
https://doi.org/10.1016/j.nucmedbio.2023.108366 |
| 11 |
2022 |
Marilia Barreca, Noémie Lang, Chiara Tarantelli, Filippo Spriano, Paola Barraja, Francesco Bertoni. Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences, Exploration of Targeted Anti-tumor Therapy. 2022; 763.
https://doi.org/10.37349/etat.2022.00112 |
| 12 |
2023 |
Rafael F. A. Gomes, Bruno M. F. Gonçalves, Késsia H. S. Andrade, Bárbara B. Sousa, Nuno Maulide, Gonçalo J. L. Bernardes, Carlos A. M. Afonso. Unlocking the Potential of Bio‐Based Nitrogen‐Rich Furanic Platforms as Biomass Synthons, Angewandte Chemie. 2023; 135: e202304449.
https://doi.org/10.1002/ange.202304449 |
